{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:57:03Z","timestamp":1791327423850,"version":"4.3.1"},"reference-count":57,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceuticals International AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Secondary immunodeficiency disease (SID) is a complex, heterogeneous condition that occurs when extrinsic factors weaken the immune system. Expert consensus guidelines recommend immunoglobulin replacement therapy to manage immunoglobulin G (IgG) levels and mitigate severe, recurrent, and persistent infections. Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% is a dual-vial unit of IgG and recombinant human hyaluronidase; the latter enables absorption of higher volumes of IgG than conventional subcutaneous therapies. Methods: For this systematic literature review, Embase, MEDLINE\u00ae, and the Cochrane Library were searched on 9 August 2023, with supplemental congress searches. Results: Eight studies fulfilled the inclusion criteria, reporting real-world evidence of the clinical effectiveness, safety, and tolerability of fSCIG 10% in 183 patients with SID in Europe from September 2014 to August 2021. The potential causes of SID were primarily hematological malignancies, most commonly chronic lymphocytic leukemia. Treatment was typically administered at 4-week or 3-week intervals, with doses of approximately 0.4 g\/kg\/month. Infections were rare during follow-up, with numerical reductions observed after fSCIG 10% treatment initiation compared with the period before initiation. Adverse reactions, including local infusion site reactions, and tolerability events were uncommon. Conclusions: Given the recency of fSCIG 10% use in patients with SID, there are opportunities for future research to better understand survival and patient-reported outcomes after receiving this treatment. Despite SID heterogeneity, this study demonstrates the feasibility of fSCIG 10% treatment for this condition.<\/jats:p>","DOI":"10.3390\/jcm14041203","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T06:06:06Z","timestamp":1739340366000},"page":"1203","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-World Effectiveness, Safety, and Tolerability of Facilitated Subcutaneous Immunoglobulin 10% in Secondary Immunodeficiency Disease: A Systematic Literature Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8197-9895","authenticated-orcid":false,"given":"Maria","family":"Dimou","sequence":"first","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, 15772 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4567-8216","authenticated-orcid":false,"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[{"name":"Unit of Internal Medicine \u201cGuido Baccelli\u201d, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, Piazza Giulio Cesare, 11, I-70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9585-6167","authenticated-orcid":false,"given":"Silvia","family":"S\u00e1nchez-Ram\u00f3n","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico San Carlos, Complutense University of Madrid, E-28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-5041","authenticated-orcid":false,"given":"Ewa","family":"Karakulska-Prystupiuk","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikte","family":"Lionikaite","sequence":"additional","affiliation":[{"name":"Oxford PharmaGenesis, Oxford OX13 5QJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6491-6953","authenticated-orcid":false,"given":"Csaba","family":"Siffel","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Cambridge, MA 02142, USA"},{"name":"College of Allied Health Sciences, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Anderson-Smits","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Kamieniak","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Patel, S.Y., Carbone, J., and Jolles, S. (2019). The expanding field of secondary antibody deficiency: Causes, diagnosis, and management. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00033"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jaci.2024.01.011","article-title":"Validating inborn error of immunity prevalence and risk with nationally representative electronic health record data","volume":"153","author":"Rider","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7861\/clinmedicine.16-6-571","article-title":"Secondary antibody deficiency\u2014Causes and approach to diagnosis","volume":"16","author":"Srivastava","year":"2016","journal-title":"Clin. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Duraisingham, S.S., Buckland, M., Dempster, J., Lorenzo, L., Grigoriadou, S., and Longhurst, H.J. (2014). Primary vs. secondary antibody deficiency: Clinical features and infection outcomes of immunoglobulin replacement. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100324"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ochoa-Grullon, J., Guevara-Hoyer, K., Perez Lopez, C., Perez de Diego, R., Pena Cortijo, A., Polo, M., Mateo Morales, M., Anguita Mandley, E., Jimenez Garcia, C., and Bolanos, E. (2022). Combined immune defect in B-cell lymphoproliferative disorders is associated with severe infection and cancer progression. Biomedicines, 10.","DOI":"10.3390\/biomedicines10082020"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/ejh.13580","article-title":"Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus","volume":"106","author":"Jolles","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_8","unstructured":"NHS England (2025, February 04). Commissioning Criteria Policy for the Use of Therapeutic Immunoglobulin (Ig) England. Available online: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2021\/12\/ccp-for-the-use-of-therapeutic-immunoglobulin-england-2024-v4.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.6004\/jnccn.2015.0167","article-title":"Multiple myeloma, Version 2.2016: Clinical practice guidelines in oncology","volume":"13","author":"Anderson","year":"2015","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Dimou, M., Abuzakouk, M., Al Ahmad, M., Al Farsi, K., Alhuraiji, A., Al Roqi, F., Alsaeed, A., Alzahrani, M., Bazarbachi, A., and Cherif, H. (2024). Management of secondary immunodeficiency in hematological malignancies: A Delphi Consensus from the Middle East. Front. Hematol., 3.","DOI":"10.3389\/frhem.2024.1347708"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/1744666X.2020.1807328","article-title":"A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants","volume":"16","author":"Waser","year":"2020","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: A practical approach","volume":"188","author":"Jolles","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jaci.2008.08.012","article-title":"Immunoglobulin therapy: Methods of delivery","volume":"122","author":"Ballow","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","first-page":"76","article-title":"New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients","volume":"6","author":"Krivan","year":"2017","journal-title":"Am. J. Clin. Exp. Immunol."},{"key":"ref_17","unstructured":"European Medicines Agency (2024, March 19). Summary of Product Characteristics\u2014HyQvia 100 mg\/mL Solution for Infusion for Subcutaneous Use. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hyqvia-epar-product-information_en.pdf."},{"key":"ref_18","unstructured":"US Food and Drug Administration (2024, June 05). Prescribing Information\u2014HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Solution, for Subcutaneous Administration, Available online: https:\/\/www.fda.gov\/media\/89844\/download."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/ITT.S31136","article-title":"Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency","volume":"2","author":"Jolles","year":"2013","journal-title":"Immunotargets Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/imt-2017-0092","article-title":"Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases","volume":"9","author":"Wasserman","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","article-title":"Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency","volume":"130","author":"Wasserman","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/imt-2016-0066","article-title":"Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: Long-term efficacy, safety and tolerability","volume":"8","author":"Wasserman","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10875-016-0298-x","article-title":"Long-term tolerability, safety, and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency","volume":"36","author":"Wasserman","year":"2016","journal-title":"J. Clin. Immunol."},{"key":"ref_24","unstructured":"US Food and Drug Administration (2024, March 19). Guidance for Industry. Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency, Available online: https:\/\/www.fda.gov\/media\/124333\/download."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wiesik-Szewczyk, E., Soldacki, D., Paczek, L., and Jahnz-Rozyk, K. (2020). Facilitated subcutaneous immunoglobulin replacement therapy in clinical practice: A two center, long-term retrospective observation in adults with primary immunodeficiencies. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00981"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"AB220","DOI":"10.1016\/j.jaci.2015.12.853","article-title":"Real-world use of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin G (IG) (IGHy) in patients with primary immunodeficiency disorders (PIDD)","volume":"137","author":"Rosenbach","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s12325-020-01264-7","article-title":"Clinical practice experience with HyQvia in adults using alternative dosing regimens and pediatric patients: A retrospective study","volume":"37","author":"Wasserman","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3163\/1536-5050.104.3.014","article-title":"De-duplication of database search results for systematic reviews in EndNote","volume":"104","author":"Bramer","year":"2016","journal-title":"J. Med. Libr. Assoc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_30","unstructured":"Wells, G.A., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., and Tugwell, P. (2023, May 31). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available online: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s10875-023-01470-2","article-title":"Facilitated subcutaneous immunoglobulin treatment in patients with immunodeficiencies: The FIGARO study","volume":"43","author":"Borte","year":"2023","journal-title":"J. Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1097\/01.HS9.0000849300.97009.0e","article-title":"P1611: Insights into facilitated immunoglobulin (fSCIG) use in patients with secondary immunodeficiency diseases: Final results from the FIGARO study","volume":"6","author":"Dimou","year":"2024","journal-title":"HemaSphere"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Dimou, M., Speletas, M., Milito, C., Pyzik, A., Huscher, D., Kamieniak, M., Pittrow, D., and Borte, M. (2023). Insights into facilitated subcutaneous immunoglobulin use in patients with secondary immunodeficiency diseases: A FIGARO subgroup analysis. Cancers, 15.","DOI":"10.3390\/cancers15184524"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10238-020-00633-4","article-title":"Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG.; HyQvia) in immunodeficiency diseases: Real-life data from a monocentric experience","volume":"20","author":"Angelotti","year":"2020","journal-title":"Clin. Exp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2217\/imt-2021-0167","article-title":"Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases","volume":"14","author":"Baumann","year":"2022","journal-title":"Immunotherapy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.21873\/anticanres.12712","article-title":"Efficacy-safety of facilitated subcutaneous immunoglobulin in immunodeficiency due to hematological malignancies. a single-center retrospective analysis","volume":"38","author":"Dimou","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1111\/jocn.14580","article-title":"Experiences of the burden of treatment\u2014Patient reports of facilitated subcutaneous immunoglobulin treatment in adults with immunodeficiency","volume":"27","author":"Petersson","year":"2018","journal-title":"J. Clin. Nurs."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2217\/imt-2019-0175","article-title":"Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients","volume":"12","author":"Pittrow","year":"2020","journal-title":"Immunotherapy"},{"key":"ref_39","first-page":"48","article-title":"Safety and efficacy of recombinant human hyaluronidase facilitated subcutaneous infusion of immunoglobulins in patients with multiple myeloma","volume":"5","author":"Pavan","year":"2021","journal-title":"HemaSphere"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1016\/j.jval.2021.11.1213","article-title":"POSA387 Healthcare resource utilization and direct medical costs in French patients receiving treatment for hypogammaglobulinemia: A national cohort study","volume":"25","author":"Borget","year":"2022","journal-title":"Value Health"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5414\/CP204473","article-title":"Association between serum IgG concentrations and the incidence of infections in patients with chronic lymphocytic leukemia and secondary immunodeficiency under treatment with Privigen","volume":"62","author":"Otremba","year":"2024","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tmrv.2016.06.006","article-title":"Subcutaneous immunoglobulin therapy for hypogammaglobulinemia secondary to malignancy or related drug therapy","volume":"31","author":"Windegger","year":"2017","journal-title":"Tranfus Med. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/vox.12760","article-title":"Cost\u2013utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency","volume":"114","author":"Windegger","year":"2019","journal-title":"Vox Sang."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/ajco.13515","article-title":"Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy","volume":"17","author":"Windegger","year":"2021","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1055\/s-2002-36700","article-title":"Aging and thrombosis","volume":"28","author":"Wilkerson","year":"2002","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","article-title":"The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols","volume":"152","author":"Grace","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2018-01-827949","article-title":"Thromboembolism in acute lymphoblastic leukemia: Results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years","volume":"131","author":"Rank","year":"2018","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2008-08-175745","article-title":"Venous thromboembolism in patients with acute leukemia: Incidence, risk factors, and effect on survival","volume":"113","author":"Ku","year":"2009","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1182\/bloodadvances.2021004355","article-title":"Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality","volume":"5","author":"Vellenga","year":"2021","journal-title":"Blood Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/CIA.S4308","article-title":"Use of anticoagulants in elderly patients: Practical recommendations","volume":"4","author":"Righini","year":"2009","journal-title":"Clin. Interv. Aging"},{"key":"ref_51","first-page":"420","article-title":"Facilitated subcutaneous immunoglobulin (fSCIg) in autoimmune cytopenias associated with common variable immunodeficiency","volume":"19","author":"Pedini","year":"2017","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2217\/imt-2016-0035","article-title":"Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin therapy in complicated primary antibody deficiencies","volume":"8","author":"Danieli","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3810\/pgm.2011.09.2474","article-title":"Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases","volume":"123","author":"Stein","year":"2011","journal-title":"Postgrad. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Di Lernia, G., Leone, P., Solimando, A.G., Buonavoglia, A., Saltarella, I., Ria, R., Ditonno, P., Silvestris, N., Crudele, L., and Vacca, A. (2020). Bortezomib treatment modulates autophagy in multiple myeloma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020552"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clim.2017.11.014","article-title":"Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: A randomized trial","volume":"191","author":"Vacca","year":"2018","journal-title":"Clin. Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1203\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:32:03Z","timestamp":1760027523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14041203"],"URL":"https:\/\/doi.org\/10.3390\/jcm14041203","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}